Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment
The aim of this study was to define the factors that -affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) -patients treated with second-line chemotherapy. We retrospectively reviewed the data of 59 patients with MGC or GEJ adeno...
Gespeichert in:
| Veröffentlicht in: | Acta gastro-enterologica belgica 2016-04, Vol.79 (2), p.211-215 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 215 |
|---|---|
| container_issue | 2 |
| container_start_page | 211 |
| container_title | Acta gastro-enterologica belgica |
| container_volume | 79 |
| creator | Turkmen, Esma Erdogan, Bulent Kodaz, Hilmi Hacibekiroglu, Ilhan Onal, Yılmaz Uzunoglu, Sernaz Kilic, Nilufer Cicin, Irfan |
| description | The aim of this study was to define the factors that -affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) -patients treated with second-line chemotherapy.
We retrospectively reviewed the data of 59 patients with MGC or GEJ adenocarcinoma who received second-line treatment.
The median age was 54 years old (26-77). Response to second-line treatment was strongly associated with disease control with first-line treatment (p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1802745137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1802745137</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-7dca0a176ded1fb67cc8d758ca9d92ef68b136930c4b44261f38e4dd3ee7c9e43</originalsourceid><addsrcrecordid>eNo1UMtqwzAQ9KGlCWl-oejYi8F6xLKPJfQFgfbQns1aWqcOtuRq5UCu_fKqJN3LzLIzA7NX2ZLrSuVSCL3I1kSHIk2teCGKm2whtKxErYpl9vPuKbIp-H1Aot47RnM49kcYGDgYTtQT8x0bMQJFiL1h-0RCQnD2zD2Sn75gj8lzmJ2JfykGnMHApmRBF4lBF9NKaLyz-dA7ZDEgxDEdb7PrDgbC9QVX2efT48f2Jd-9Pb9uH3b5JDiPubYGCuC6tGh515bamMrqTWWgtrXArqxaLstaFka1SomSd7JCZa1E1KZGJVfZ_Tk3tf2ekWIz9mRwGMChn6nhVSG02nCpk_TuIp3bEW0zhX6EcGr-_yZ_AavGbcg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1802745137</pqid></control><display><type>article</type><title>Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Turkmen, Esma ; Erdogan, Bulent ; Kodaz, Hilmi ; Hacibekiroglu, Ilhan ; Onal, Yılmaz ; Uzunoglu, Sernaz ; Kilic, Nilufer ; Cicin, Irfan</creator><creatorcontrib>Turkmen, Esma ; Erdogan, Bulent ; Kodaz, Hilmi ; Hacibekiroglu, Ilhan ; Onal, Yılmaz ; Uzunoglu, Sernaz ; Kilic, Nilufer ; Cicin, Irfan</creatorcontrib><description>The aim of this study was to define the factors that -affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) -patients treated with second-line chemotherapy.
We retrospectively reviewed the data of 59 patients with MGC or GEJ adenocarcinoma who received second-line treatment.
The median age was 54 years old (26-77). Response to second-line treatment was strongly associated with disease control with first-line treatment (p < 0.01). Median progression-free survival (PFS), overall survival (OS) and post-progression survival (PPS) were 3.2 (95% CI : 2.63-3.80), 6.5 (95% CI : 3.78-9.35) and 2.7 months (95% CI : 1.89-3.68), respectively. PFS (r = 0.55, p < 0.01) and PPS (r = 0.89, p < 0.01) were correlated with OS. Response to second-line treatment was independently related to PFS (HR : 0.12 95%CI : 0.53-0.26, p < 0.001). Having an ECOG 0 performance status (HR : 0.42 ; 95%CI : 0.21-0.86, p = 0.02) and response to second-line therapy (HR : 0.47 ; 95%CI : 0.25-0.85, p = 0.01) were independently associated with OS.
PPS and PFS were correlated with OS after second-line treatment of MGC. Response to second-line treatment prolonged OS by increasing PFS, and having an ECOG 0 PS prolonged OS by increasing PPS.</description><identifier>ISSN: 1784-3227</identifier><identifier>PMID: 27382940</identifier><language>eng</language><publisher>Belgium</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - secondary ; Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Camptothecin - analogs & derivatives ; Camptothecin - therapeutic use ; Capecitabine - therapeutic use ; Cisplatin - administration & dosage ; Disease Progression ; Disease-Free Survival ; Epirubicin - administration & dosage ; Esophagogastric Junction - pathology ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - therapeutic use ; Humans ; Leucovorin - therapeutic use ; Male ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Organoplatinum Compounds - therapeutic use ; Peritoneal Neoplasms - drug therapy ; Peritoneal Neoplasms - secondary ; Retrospective Studies ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - pathology ; Survival Rate ; Taxoids - administration & dosage ; Taxoids - therapeutic use</subject><ispartof>Acta gastro-enterologica belgica, 2016-04, Vol.79 (2), p.211-215</ispartof><rights>Acta Gastro-Enterologica Belgica.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27382940$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turkmen, Esma</creatorcontrib><creatorcontrib>Erdogan, Bulent</creatorcontrib><creatorcontrib>Kodaz, Hilmi</creatorcontrib><creatorcontrib>Hacibekiroglu, Ilhan</creatorcontrib><creatorcontrib>Onal, Yılmaz</creatorcontrib><creatorcontrib>Uzunoglu, Sernaz</creatorcontrib><creatorcontrib>Kilic, Nilufer</creatorcontrib><creatorcontrib>Cicin, Irfan</creatorcontrib><title>Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment</title><title>Acta gastro-enterologica belgica</title><addtitle>Acta Gastroenterol Belg</addtitle><description>The aim of this study was to define the factors that -affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) -patients treated with second-line chemotherapy.
We retrospectively reviewed the data of 59 patients with MGC or GEJ adenocarcinoma who received second-line treatment.
The median age was 54 years old (26-77). Response to second-line treatment was strongly associated with disease control with first-line treatment (p < 0.01). Median progression-free survival (PFS), overall survival (OS) and post-progression survival (PPS) were 3.2 (95% CI : 2.63-3.80), 6.5 (95% CI : 3.78-9.35) and 2.7 months (95% CI : 1.89-3.68), respectively. PFS (r = 0.55, p < 0.01) and PPS (r = 0.89, p < 0.01) were correlated with OS. Response to second-line treatment was independently related to PFS (HR : 0.12 95%CI : 0.53-0.26, p < 0.001). Having an ECOG 0 performance status (HR : 0.42 ; 95%CI : 0.21-0.86, p = 0.02) and response to second-line therapy (HR : 0.47 ; 95%CI : 0.25-0.85, p = 0.01) were independently associated with OS.
PPS and PFS were correlated with OS after second-line treatment of MGC. Response to second-line treatment prolonged OS by increasing PFS, and having an ECOG 0 PS prolonged OS by increasing PPS.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - secondary</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - therapeutic use</subject><subject>Capecitabine - therapeutic use</subject><subject>Cisplatin - administration & dosage</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Epirubicin - administration & dosage</subject><subject>Esophagogastric Junction - pathology</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - therapeutic use</subject><subject>Humans</subject><subject>Leucovorin - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Peritoneal Neoplasms - drug therapy</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Retrospective Studies</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - pathology</subject><subject>Survival Rate</subject><subject>Taxoids - administration & dosage</subject><subject>Taxoids - therapeutic use</subject><issn>1784-3227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UMtqwzAQ9KGlCWl-oejYi8F6xLKPJfQFgfbQns1aWqcOtuRq5UCu_fKqJN3LzLIzA7NX2ZLrSuVSCL3I1kSHIk2teCGKm2whtKxErYpl9vPuKbIp-H1Aot47RnM49kcYGDgYTtQT8x0bMQJFiL1h-0RCQnD2zD2Sn75gj8lzmJ2JfykGnMHApmRBF4lBF9NKaLyz-dA7ZDEgxDEdb7PrDgbC9QVX2efT48f2Jd-9Pb9uH3b5JDiPubYGCuC6tGh515bamMrqTWWgtrXArqxaLstaFka1SomSd7JCZa1E1KZGJVfZ_Tk3tf2ekWIz9mRwGMChn6nhVSG02nCpk_TuIp3bEW0zhX6EcGr-_yZ_AavGbcg</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Turkmen, Esma</creator><creator>Erdogan, Bulent</creator><creator>Kodaz, Hilmi</creator><creator>Hacibekiroglu, Ilhan</creator><creator>Onal, Yılmaz</creator><creator>Uzunoglu, Sernaz</creator><creator>Kilic, Nilufer</creator><creator>Cicin, Irfan</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20160401</creationdate><title>Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment</title><author>Turkmen, Esma ; Erdogan, Bulent ; Kodaz, Hilmi ; Hacibekiroglu, Ilhan ; Onal, Yılmaz ; Uzunoglu, Sernaz ; Kilic, Nilufer ; Cicin, Irfan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-7dca0a176ded1fb67cc8d758ca9d92ef68b136930c4b44261f38e4dd3ee7c9e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - secondary</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - therapeutic use</topic><topic>Capecitabine - therapeutic use</topic><topic>Cisplatin - administration & dosage</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Epirubicin - administration & dosage</topic><topic>Esophagogastric Junction - pathology</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - therapeutic use</topic><topic>Humans</topic><topic>Leucovorin - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Peritoneal Neoplasms - drug therapy</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Retrospective Studies</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - pathology</topic><topic>Survival Rate</topic><topic>Taxoids - administration & dosage</topic><topic>Taxoids - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turkmen, Esma</creatorcontrib><creatorcontrib>Erdogan, Bulent</creatorcontrib><creatorcontrib>Kodaz, Hilmi</creatorcontrib><creatorcontrib>Hacibekiroglu, Ilhan</creatorcontrib><creatorcontrib>Onal, Yılmaz</creatorcontrib><creatorcontrib>Uzunoglu, Sernaz</creatorcontrib><creatorcontrib>Kilic, Nilufer</creatorcontrib><creatorcontrib>Cicin, Irfan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Acta gastro-enterologica belgica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turkmen, Esma</au><au>Erdogan, Bulent</au><au>Kodaz, Hilmi</au><au>Hacibekiroglu, Ilhan</au><au>Onal, Yılmaz</au><au>Uzunoglu, Sernaz</au><au>Kilic, Nilufer</au><au>Cicin, Irfan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment</atitle><jtitle>Acta gastro-enterologica belgica</jtitle><addtitle>Acta Gastroenterol Belg</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>79</volume><issue>2</issue><spage>211</spage><epage>215</epage><pages>211-215</pages><issn>1784-3227</issn><abstract>The aim of this study was to define the factors that -affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) -patients treated with second-line chemotherapy.
We retrospectively reviewed the data of 59 patients with MGC or GEJ adenocarcinoma who received second-line treatment.
The median age was 54 years old (26-77). Response to second-line treatment was strongly associated with disease control with first-line treatment (p < 0.01). Median progression-free survival (PFS), overall survival (OS) and post-progression survival (PPS) were 3.2 (95% CI : 2.63-3.80), 6.5 (95% CI : 3.78-9.35) and 2.7 months (95% CI : 1.89-3.68), respectively. PFS (r = 0.55, p < 0.01) and PPS (r = 0.89, p < 0.01) were correlated with OS. Response to second-line treatment was independently related to PFS (HR : 0.12 95%CI : 0.53-0.26, p < 0.001). Having an ECOG 0 performance status (HR : 0.42 ; 95%CI : 0.21-0.86, p = 0.02) and response to second-line therapy (HR : 0.47 ; 95%CI : 0.25-0.85, p = 0.01) were independently associated with OS.
PPS and PFS were correlated with OS after second-line treatment of MGC. Response to second-line treatment prolonged OS by increasing PFS, and having an ECOG 0 PS prolonged OS by increasing PPS.</abstract><cop>Belgium</cop><pmid>27382940</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1784-3227 |
| ispartof | Acta gastro-enterologica belgica, 2016-04, Vol.79 (2), p.211-215 |
| issn | 1784-3227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1802745137 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - secondary Adult Aged Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - analogs & derivatives Camptothecin - therapeutic use Capecitabine - therapeutic use Cisplatin - administration & dosage Disease Progression Disease-Free Survival Epirubicin - administration & dosage Esophagogastric Junction - pathology Female Fluorouracil - administration & dosage Fluorouracil - therapeutic use Humans Leucovorin - therapeutic use Male Middle Aged Neoplasm Recurrence, Local - drug therapy Organoplatinum Compounds - therapeutic use Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - secondary Retrospective Studies Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Survival Rate Taxoids - administration & dosage Taxoids - therapeutic use |
| title | Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T18%3A46%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Post%20progression%20survival%20analysis%20of%20metastatic%20gastric%20and%20gastroesophageal%20junction%20cancer%20patients%20after%20second-line%20treatment&rft.jtitle=Acta%20gastro-enterologica%20belgica&rft.au=Turkmen,%20Esma&rft.date=2016-04-01&rft.volume=79&rft.issue=2&rft.spage=211&rft.epage=215&rft.pages=211-215&rft.issn=1784-3227&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1802745137%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1802745137&rft_id=info:pmid/27382940&rfr_iscdi=true |